Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
09 2023
Historique:
received: 11 04 2023
revised: 29 06 2023
accepted: 05 07 2023
medline: 29 8 2023
pubmed: 14 8 2023
entrez: 13 8 2023
Statut: ppublish

Résumé

Invasive lobular carcinoma (ILC) represents up to 15% of all breast carcinomas. While the proportion of women with overweight and obesity increases globally, the impact of body mass index (BMI) at primary diagnosis on clinicopathological features of ILC and the prognosis of the patients has not been investigated yet. We performed a multicentric retrospective study including patients diagnosed with non-metastatic pure ILC. The association of BMI at diagnosis with clinicopathological variables was assessed using linear or multinomial logistic regression. Univariable and multivariable survival analyses were performed to evaluate the association of BMI with disease-free survival (DFS), distant recurrence-free survival (DRFS), and overall survival (OS). The data of 2856 patients with ILC and available BMI at diagnosis were collected, of which 2570/2856 (90.0%) had oestrogen receptor (ER)-positive and human epidermal growth factor receptor (HER2) not amplified/overexpressed (ER+/HER2-) ILC. Of these 2570 patients, 80 were underweight (3.1%), 1410 were lean (54.9%), 712 were overweight (27.7%), and 368 were obese (14.3%). Older age at diagnosis, a higher tumour grade, a larger tumour size, a nodal involvement, and multifocality were associated with a higher BMI. In univariable models, higher BMI was associated with worse outcomes for all end-points (DFS: hazard ratio (HR) 1.21, 95CI 1.12-1.31, p value<0.01; DRFS: HR 1.25, 95CI 1.12-1.40, p value<0.01; OS: HR 1.25, 95CI 1.13-1.37, p value<0.01). This association was not statistically significant in multivariable analyses (DFS: HR 1.09, 95CI 0.99-1.20, p value 0.08; DRFS: HR 1.03, 95CI 0.89-1.20, p value 0.67; OS: HR 1.11, 95CI 0.99-1.24, p value 0.08), whereas grade, tumour size, and nodal involvement were still prognostic for all end-points. Worse prognostic factors such as higher grade, larger tumour size, and nodal involvement are associated with higher BMI in ER+/HER2- ILC, while there was no statistical evidence for an independent prognostic role for BMI. Therefore, we hypothesise that the effect of BMI on survival could be mediated through its association with these clinicopathological variables.

Identifiants

pubmed: 37573673
pii: S0959-8049(23)00340-4
doi: 10.1016/j.ejca.2023.112988
pii:
doi:

Substances chimiques

Receptors, Estrogen 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112988

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Karen Van Baelen (K)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Department of Gynecological Oncology, University Hospitals Leuven, Leuven, Belgium.

Ha-Linh Nguyen (HL)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.

Anne-Sophie Hamy-Petit (AS)

Department of Medical Oncology, Institut Curie, Paris, France.

François Richard (F)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.

Maria Margarete Karsten (MM)

Department of Gynecology and Breast Center, Charité Universitätsmedizin Berlin, Berlin, Germany.

Guilherme Nader Marta (G)

Institut Jules Bordet & l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium.

Peter Vermeulen (P)

Translational Cancer Research Unit, Center for Oncological Research, Faculty of Medicine and Health Sciences, University of Antwerp & GZA Hospital Sint-Augustinus, Antwerp, Belgium.

Aullene Toussaint (A)

Department of Medical Oncology, Institut Curie, Paris, France.

Fabien Reyal (F)

Department of Surgery, Institut Curie, Paris, France.

Anne Vincent-Salomon (A)

Department of Pathology, Université Paris Sciences Lettres, Institut Curie, Paris, France.

Luc Dirix (L)

Translational Cancer Research Unit, Center for Oncological Research, Faculty of Medicine and Health Sciences, University of Antwerp & GZA Hospital Sint-Augustinus, Antwerp, Belgium.

Adam David Dordevic (AD)

Department of Gynecology and Breast Center, Charité Universitätsmedizin Berlin, Berlin, Germany.

Evandro de Azambuja (E)

Institut Jules Bordet & l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium.

Denis Larsimont (D)

Institut Jules Bordet & l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium.

Ottavia Amato (O)

Institut Jules Bordet & l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium; Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, Padova, Italy.

Marion Maetens (M)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.

Maxim De Schepper (M)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Department of Pathology, University Hospitals Leuven, Leuven, Belgium.

Tatjana Geukens (T)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.

Sileny N Han (SN)

Department of Gynecological Oncology, University Hospitals Leuven, Leuven, Belgium.

Thaïs Baert (T)

Department of Gynecological Oncology, University Hospitals Leuven, Leuven, Belgium.

Kevin Punie (K)

Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.

Hans Wildiers (H)

Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.

Ann Smeets (A)

Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium.

Ines Nevelsteen (I)

Department of Surgical Oncology, University Hospitals Leuven, Leuven, Belgium.

Giuseppe Floris (G)

Department of Pathology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Translational Cell & Tissue Research, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.

Elia Biganzoli (E)

Unit of Medical Statistics, Biometry and Epidemiology "Giulio A. Maccacaro", Department of Clinical Sciences and Community Health & DSRC, University of Milan, Milan, Italy.

Patrick Neven (P)

Department of Gynecological Oncology, University Hospitals Leuven, Leuven, Belgium.

Christine Desmedt (C)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium. Electronic address: christine.desmedt@kuleuven.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH